How does probenecid alter tigecycline’s renal clearance?
Probenecid inhibits renal tubular secretion by blocking transporters such as OAT1/OAT3. When probenecid is given with tigecycline, it reduces tigecycline’s renal elimination pathway that depends on tubular secretion, which lowers tigecycline’s renal clearance and increases its systemic exposure.
What mechanism drives the change in tigecycline clearance?
Tigecycline elimination includes a fraction that involves kidney-based transport and secretion. Probenecid interferes with that transporter-mediated secretion step in the kidney, so less tigecycline is cleared into urine. The net effect is reduced renal clearance rather than increased filtration.
What does this mean for dosing and drug exposure?
If probenecid reduces tigecycline renal clearance, tigecycline concentrations can rise, potentially increasing exposure-related effects. This can matter most in patients with impaired kidney function or when both drugs are used together.
Are there kidney-impairment or safety edge cases?
In patients with reduced renal function, baseline renal elimination can already be lower. Adding probenecid can further reduce the portion of clearance that relies on transporter-mediated secretion, which can magnify increases in tigecycline exposure compared with people with normal kidney function.
Could the interaction be studied using pharmacokinetic readouts?
The effect is typically identified through pharmacokinetic comparisons showing reduced tigecycline renal clearance (and often higher plasma AUC) when probenecid is coadministered, consistent with transporter blockade reducing tubular secretory clearance.
Sources
No sources were provided in the prompt, so I cannot cite specific evidence or quantify the magnitude of the clearance change.